SIREN : 483272845
JARRYPHARM is a French company founded 20 years ago, specialized in the sector Location de terrains et d'autres biens immobiliers. Based in BAIE-MAHAULT (97122), this company of category ETI shows in 2024 a revenue of 489 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 488 760 € | 488 760 € | 488 992 € | 487 387 € | 484 594 € | 484 194 € | 482 994 € | 493 795 € | 497 956 € |
| Net income | 45 081 € | -126 564 € | 25 649 € | 11 255 € | 75 463 € | 169 129 € | 166 926 € | -492 307 € | 23 255 € |
| EBITDA | 435 897 € | 433 592 € | 436 190 € | 425 991 € | 435 934 € | 435 229 € | 417 797 € | 124 863 € | 57 593 € |
| Net margin | 9.2% | -25.9% | 5.2% | 2.3% | 15.6% | 34.9% | 34.6% | -99.7% | 4.7% |
In 2024, JARRYPHARM achieves revenue of 489 k€. Activity remains stable over the period (CAGR: -0.2%). Slight decline of 0% vs 2023. After deducting consumption (0 €), gross margin stands at 489 k€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 436 k€, representing 89.2% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 45 k€, i.e. 9.2% of revenue. This profit can be retained or distributed to shareholders.
488 760 €
488 760 €
435 897 €
221 386 €
45 081 €
89.2%
The debt ratio (= Financial debt / Equity x 100) stands at 152%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 40%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 4.4 years of cash flow to repay all financial debt. This ratio remains within usual banking standards. Cash flow represents 85.0% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
151.535%
39.663%
85.026%
4.434
70.8%
In 2024, the debt ratio of JARRYPHARM (151.53) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of JARRYPHARM (39.7%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2024, the repayment capacity of JARRYPHARM (4.43) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 5392.96. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 6.0x. Operating income very largely covers interest expenses: high safety margin.
5392.959
5.989
In 2024, the liquidity ratio of JARRYPHARM (5392.96) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of JARRYPHARM (6.0x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. WCR is negative (-644 days): operations structurally generate cash. Notable WCR improvement over the period (-721%), freeing up cash.
-874 597 €
0 j
0 j
0 j
-644 j
Based on 169 transactions of similar company sales in 2024, the value of JARRYPHARM is estimated at 1 400 187 € (range 386 736€ - 2 510 419€). With an EBITDA of 435 897€, the sector multiple of 5.6x is applied. The price/revenue ratio is 0.81x (in line with sector norms). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 169 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare JARRYPHARM with other companies in the same sector:
Voir toutes les statistiques du secteur Location de terrains et d'autres biens immobiliers
The revenue of JARRYPHARM in 2024 is 489 k€.
Yes, JARRYPHARM generated a net profit of 45 k€ in 2024.
The headquarters of JARRYPHARM is located in BAIE-MAHAULT (97122), in the department Guadeloupe.
The tax return of JARRYPHARM is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
JARRYPHARM operates in the sector Location de terrains et d'autres biens immobiliers (NAF code 68.20B). See the 'Sector positioning' section above to compare the company with its competitors.